Clinical Trial

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

Name: A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors — clinical trial record (NCT06963398)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.

Trial Details

NCT Number	NCT06963398
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Advanced Solid Tumors
Enrollment	520 participants
Start Date	2025-05-15
Primary Completion	2029-04-30 (estimated)
Study Completion	2029-08-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-09